ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "comparative effectiveness"

  • Abstract Number: 0010 • ACR Convergence 2020

    Antirheumatic Disease Therapies in Patients with COVID-19: A Systematic Review and Meta-analysis

    Michael Putman1, Yu Pei Eugenia Chock2, Herman Tam3, Alfred Kim4, Sebastian Sattui5, Francis Berenbaum6, Maria (Maio) Danila7, Peter Korsten8, Catalina Sanchez Alvarez9, Jeffrey Sparks10, Laura Coates11, Candace Palmerlee12, Andrea Pierce13, Arundathi Jayatilleke14, Sindhu Johnson15, Adam Kilian16, Jean Liew17, Larry Prokop9, Hassan Murad9, Rebecca Grainger18, Zachary Wallace19 and Ali Duarte-Garcia9, 1Northwestern University, Chicago, IL, 2Yale School of Medicine, Greenwich, CT, 3The Hospital for Sick Children, Toronto, ON, Canada, 4Washington University School of Medicine, St. Louis, MO, 5Hospital for Special Surgery, New York, NY, 6Sorbonne Universit�, Paris, France, 7University of Alabama at Birmingham (UAB), Birmingham, AL, 8University Medical Center Göttingen, Gottingen, Germany, 9Mayo Clinic, Rochester, MN, 10Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 11University of Oxford, Oxford, United Kingdom, 1212. Patient Research Partner, Berkeley, CA, 13Patient Research Partner, New York City, 14Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 15University of Toronto, Toronto, ON, Canada, 16George Washington University, Washington, DC, 17University of Washington, Seattle, WA, 18University of Otago, Wellington, New Zealand, 19Massachusetts General Hospital, Newton, MA

    Background/Purpose: Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. There has been particular interest in the antimalarial agent…
  • Abstract Number: 0581 • ACR Convergence 2020

    A Proposed Economic Framework to Model the Consequences of Psoriatic Arthritis Disease Domains

    Jacquelyn Chou1, Ervant Maksabedian2, David Collier3 and Howard Thom4, 1PRECISION heor, Los Angeles, CA, 2Amgen Inc., LOS ANGELES, CA, 3Amgen, Thousand Oaks, CA, 4University of Bristol, Bristol, England, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) manifests heterogeneous signs and symptoms (e.g., dactylitis, enthesitis, axial involvement, skin- and nail disease), which may respond to treatments differently. While…
  • Abstract Number: 0801 • ACR Convergence 2020

    The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Xue Han2, Joe Zhuo2, Amy Schrader1, Nicole Middaugh1, Page Moore1 and Vadim Khaychuk2, 1Corrona, LLC, Waltham, MA, 2Bristol-Myers Squibb Company, Princeton, NJ

    Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
  • Abstract Number: 0806 • ACR Convergence 2020

    Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy

    Anthony Cordisco1 and Joshua Baker1, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Numerous clinical trials have been published in rheumatoid arthritis (RA), but comparing efficacies of disease-modifying anti-rheumatic drugs (DMARDs) is complicated by a lack of…
  • Abstract Number: 0832 • ACR Convergence 2020

    PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany

    Eugen Feist1, Peer-Malte Aries2, Silke Zinke3, Harald Burkhardt4, Inka Albrecht5, Oliver Bley5, Michael Obermeier6, Patrizia Sternad7, Martin Welcker7, Cornelia Kühne8, Ann-Dörthe Holst9, Niklas Thomas Baerlecken10 and Hans-Peter Tony11, 1Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, 2Rheumatologie im Struenseehaus, Hamburg, Germany, 3Outpatient Rheumatology Center Berlin-Lichtenberg, Berlin, Germany, 4Department of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, Frankfurt am Main, Germany, 5Sanofi Aventis Deutschland GmbH, Berlin, Germany, 6GKM Gesellschaft für Therapieforschung, Munich, Germany, 7MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany, 8Outpatient practice, Haldensleben, Germany, 9Outpatient practice, Ludwigslust, Germany, 10Rheumatology Cologne Dr. N. Baerlecken/Dr. T. Karger, Cologne, Germany, 11Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany

    Background/Purpose: Blockade of IL-6 signaling by sarilumab has been demonstrated to be an effective treatment approach for RA. Due to strict inclusion and exclusion criteria,…
  • Abstract Number: 0834 • ACR Convergence 2020

    Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry

    Stefano Fiore1, Lang Chen2, Cassie Clinton2, Huifeng Yun2, Amy Praestgaard3, Kerri Ford3 and Jeffrey R Curtis2, 1Sanofi, Bridgewater, NJ, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Sanofi, Cambridge, MA

    Background/Purpose: Patients with RA who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may…
  • Abstract Number: 1005 • ACR Convergence 2020

    Risk of Non-vertebral Fractures Among Rheumatoid Arthritis Patients Treated with Biologic or Targeted-Synthetic DMARDs: A Multi-Database Comparative Safety Study

    Ajinkya Pawar1, Rishi Desai1, Mengdong He1, Lily Bessette1 and Seoyoung Kim2, 1Brigham and Women's hospital, Boston, 2Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) increases risk of osteoporosis and fractures. However, limited head-to-head comparative data exists on the risk of non-vertebral osteoporotic fractures (NVFs) among…
  • Abstract Number: 1160 • ACR Convergence 2020

    Treatment Intensity and Impact on Bone Lesion Evolution and Distribution Patterns in Severe Chronic Recurrent Multifocal Osteomyelitis

    Aleksander Lenert1, T. Shawn Sato2, Sedat G Kandemirli1, Patrick Ten Eyck1 and Polly Ferguson3, 1University of Iowa, Iowa City, IA, 2University of Iowa, Iowa City, 3University of Iowa Carver College of Medicine, Iowa City, IA

    Background/Purpose: To compare bone lesion evolution and bone lesion distribution patterns identified by whole body magnetic resonance imaging (WB-MRI) by treatment intensity in patients with…
  • Abstract Number: 1241 • ACR Convergence 2020

    Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries

    Hugo Madariaga1, Juan Reyes2, Magda Gutierrez3, Dario Ponce de Leon4, Tatjana Lukic5 and Luisa Amador2, 1Centro Medico CEEN, Arequipa, Arequipa, Peru, 2Pfizer, Bogota, Cundinamarca, Colombia, 3Pfizer, Santiago, Region Metropolitana, Chile, 4PFIZER, LIMA, Peru, 5Pfizer Inc, New York, NY

    Background/Purpose: The objective of this study was to describe the efficacy, safety and patient reported outcomes in Latin-American patients with Rheumatoid Arthritis (RA) treated with…
  • Abstract Number: 1346 • ACR Convergence 2020

    Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis

    Runsheng Wang1, Abhijit Dasgupta2 and Michael Ward3, 1Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 2NIAMS, Bethesda, 3National Institutes of Health, Bethesda, MD

    Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous.  In clinical practice, both patients and…
  • Abstract Number: 1351 • ACR Convergence 2020

    Efficacy of Ixekizumab versus Adalimumab in Psoriatic Arthritis (PsA) Patients with and Without Moderate-to-severe Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study

    Lars Erik Kristensen1, Masato Okada2, William Tillett3, Soyi Liu-Leage4, Celine El Baou5, Andrew Bradley5, Gabriella Meszaros4 and Kurt de Vlam6, 1The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, 2St. Luke's International University, Tokyo, Japan, Chuo-ku, Tokyo, Japan, 3Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, 4Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, 6Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium

    Background/Purpose: Ixekizumab (IXE), a selective interleukin-17A antagonist, is approved for the treatment of active PsA, moderate-to-severe psoriasis (PsO), and radiographic/non-radiographic axial SpA in adults. The…
  • Abstract Number: 1492 • ACR Convergence 2020

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes

    Yukiko Kimura1, George Tomlinson2, Laura Schanberg3, Mary Ellen Riordan4, Anne Dennos5, Vincent Del Gaizo6, Katherine Murphy7, Pamela F. Weiss8, Brian Feldman9 and Sarah Ringold10, 1Hackensack Meridian School of Medicine, Hackensack, NJ, 2Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, 3Duke University Medical Center, Durham, NC, 4Hackensack University Medical Center, Westwood, NJ, 5Duke University, Durham, NC, 6Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, 7Lousiana Department of Public Health, New Orleans, LA, 8Children's Hospital of Philadelphia, Philadelphia, 9The Hospital for Sick Children, Toronto, ON, Canada, 10Seattle Children's, Seattle, WA

    Background/Purpose: There is uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed…
  • Abstract Number: 2067 • 2019 ACR/ARP Annual Meeting

    Comparison of Medication New User Definitions in Multi-Specialty EMR Data

    Jeffrey Curtis1, Lang Chen 1, Narender Annapureddy 2, Cassie Clinton 1, Megan Clowse 3, Millie Long 4, W. Benjamin Nowell 5, Jim Oates 6, Rennie Rhee 7, Siddarth Singh 8, Fenglong Xie 9 and Timothy Beukelman 10, 1University of Alabama at Birmingham, Birmingham, AL, 2Vanderbilt University, Nashville, TN, 3Duke University, Durham, 4University of North Carolina Chapel Hill, Chapel Hill, NC, 5Global Healthy Living Foundation, Upper Nyack, NY, 6Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, 7University of Pennsylvania, Division of Rheumatology, Philadelphia, PA, 8University California, San Diego, San Diego, 9University of Alabama at Birmingham, Birmingham, 10University of Alabama Birmingham, Birmingham, AL

    Background/Purpose: New user designs are typically preferred in pharmacoepidemiology to avoid bias. The optimal implementation of a new user design in electronic medical record (EMR)…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology